



Announcement Summary

Entity name

TELIX PHARMACEUTICALS LIMITED

Date of this announcement

Monday May 20, 2024

The +securities the subject of this notification are:

Other

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
New class - code to be confirmed	QSAM Performance Rights	4,284,000	17/05/2024

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ACN

Registration number

616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

New announcement

1.5 Date of this announcement

20/5/2024



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

Other

Please specify

Performance Rights related to QSAM acquisition disclosed in App 3B on 8 Feb 2024

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

does not have an existing ASX security code ("new class")



Part 3C - number and type of +securities the subject of this notification (new class)

New +securities**ASX +security code**

New class - code to be confirmed

+Security description

QSAM Performance Rights

+Security type

Other

ISIN code**Date the +securities the subject of this notification were issued**

17/5/2024

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

Refer to ASX release dated 8 Feb 2024 and Notice of General Meeting dated 6 March 2024 available at <https://telixpharma.com/investor-centre/asx-announcements/>

Any other information the entity wishes to provide about the +securities the subject of this notification

A total of 4,284,000 Performance Rights have been granted. The number of Performance Rights is based on the number of contingent value rights (CVRs) which can be settled through the issue of Telix ordinary shares on satisfaction of the relevant milestones. CVRs that can only be cash settled have not been included in this announcement as they do not constitute equity securities.

Please provide any further information needed to understand the circumstances in which you are notifying the issue of these +securities to ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

Not applicable



Issue details

Number of +securities

4,284,000

Were the +securities issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Refer to ASX release dated 8 Feb 2024 and Notice of General Meeting dated 6 March 2024 available at <https://telixpharma.com/investor-centre/asx-announcements/>

Purpose of the issue

To pay for the acquisition of an asset

Additional Details

Name of company or asset being acquired

QSAM Biosciences Inc (refer ASX releases 8 Feb 2024 and 3 May 2024)



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLX : ORDINARY FULLY PAID	330,455,778

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	2,523,720
TLXAP : SHARE RIGHTS	1,230,000
TLXAO : SHARE APPRECIATION RIGHTS	11,212,780
TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37	584,492
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAL : OPTION EXPIRING 27-JAN-2026 EX \$4.38	685,510
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000
New class - code to be confirmed : QSAM Performance Rights	4,284,000



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

16